• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Prometheus Biosciences Inc. (Amendment)

    2/14/23 1:58:20 PM ET
    $RXDX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RXDX alert in real time by email
    SC 13G/A 1 prometheusbio13ga.htm SC 13G/A

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

    Prometheus Biosciences, Inc.

    (Name of Issuer – as specified in its charter)

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

    74349U108

    (CUSIP Number)

    December 31, 2022

    (Date of Event which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    þ        Rule 13d-1(b)

    ¨        Rule 13d-1(c)

    ¨        Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     
     

     

    1

    NAME OF REPORTING PERSON

    Eventide Asset Management, LLC

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    ¨ (a)

    ¨ (b)

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

    5

    SOLE VOTING POWER

    1,032,938

     

    6

    SHARED VOTING POWER

    0

    7

    SOLE DISPOSITIVE POWER

    1,032,938

     

    8

    SHARED DISPOSITIVE POWER

    0

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,032,938

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ¨

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    2.2%

     

    12

    TYPE OF REPORTING PERSON

    IA

           

     

     
     

     

    1

    NAME OF REPORTING PERSON

    Finny Kuruvilla, M.D. Ph. D.

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    ¨ (a)

    ¨ (b)

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

    5

    SOLE VOTING POWER

    0

     

    6

    SHARED VOTING POWER

    1,032,938

     

    7

    SOLE DISPOSITIVE POWER

    0

     

    8

    SHARED DISPOSITIVE POWER

    1,032,938

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,032,938

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ¨

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    2.2%

     

    12

    TYPE OF REPORTING PERSON

    IN;HC

           

     

     
     

     

    1

    NAME OF REPORTING PERSON

    Robin C. John

     

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    ¨ (a)

    ¨ (b)

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

    5

    SOLE VOTING POWER

    0

     

    6

    SHARED VOTING POWER

    1,032,938

     

    7

    SOLE DISPOSITIVE POWER

    0

     

    8

    SHARED DISPOSITIVE POWER

    1,032,938

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,032,938

     

    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ¨

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    2.2%

     

    12

    TYPE OF REPORTING PERSON

    IN;HC

           

     

     
     

    Item 1. (a) Name of Issuer:

    Prometheus Biosciences, Inc. (the “Issuer”)

    (b) Address of Issuer’s Principal Executive Offices:

    3050 Science Park Road, San Diego, California, 92121

    Item 2. (a) Name of Persons Filing:

    (i) Eventide Asset Management, LLC (“Eventide”)

    (ii) Finny Kuruvilla, M.D., Ph.D. (“Kuruvilla”)

    (iii) Robin C. John (“John”)

    (b). Address of Principal Business Office or, if none, Residence:

    Eventide, Kuruvilla and John:

    One International Place, Suite 4210

    Boston, Massachusetts 02110

    (c). Citizenship or Place of Organization:

    Eventide: Delaware

    Kuruvilla: United States

    John: United States

    (d). Title of Class of Securities:

    Common Stock, $0.0001 par value per share

     

    (e). CUSIP Number:

    74349U108

    Item 3. If this statement is filed pursuant to sections 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    (a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

    (b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

    (c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

    (d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

    (e) [x] An investment adviser in accordance with section 240.13d-1(b)(1)(ii)(E);

    (f) [ ] An employee benefit plan or endowment fund in accordance with section 240.13d- 1(b)(1)(ii)(F);

    (g) [x] A parent holding company or control person in accordance with section 240.13d- 1(b)(1)(ii)(G);

    (h) [ ] A savings association as defined in section 3(b) of the Federal Deposit Insurance

    Act (12 U.S.C. 1813);

    (i) [ ] A church plan that is excluded from the definition of an investment company under

     
     

            section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

    (j) [ ] A non-U.S. institution in accordance with section 240.13d-1(b)(1)(ii)(J);

    (k) [ ] A group, in accordance with section 240.13d-1(b)(1) (ii)(K).

    If filing as a non-U.S. institution in accordance with section 240.13d-1(b)(1)(ii)(J), please specify the type of institution: __________

    Item 4. Ownership:

    Provide the following information regarding the aggregate number and percentage of the class of securities of the Issuer identified in Item 1.

    (a). Amount beneficially owned:   
       (i) Eventide:  1,032,938
       (ii) Kuruvilla:  1,032,938
       (iii) John:  1,032,938
    (b). Percent of class:   
       (i) Eventide:  2.2%
       (ii) Kuruvilla:  2.2%
       (iii) John:  2.2%
    (c). Number of shares as to which the person has:   
    (i)        Sole power to vote or to direct the vote:   
       (1) Eventide:  1,032,938
       (2) Kuruvilla:  0
       (3) John:  0
    (ii)        Shared power to vote or to direct the vote:   
        
       (1) Eventide:  0
       (2) Kuruvilla:  1,032,938
       (3) John:  1,032,938
    (iii) Sole power to dispose or to direct the disposition of:
       (1) Eventide:  1,032,938
       (2) Kuruvilla:  0
       (3) John:  0
    (iv) Shared power to dispose or to direct the disposition of:
       (1) Eventide:  0
       (2) Kuruvilla:  1,032,938
       (3) John:  1,032,938
     
     

    Item 5. Ownership of Five Percent or Less of a Class:

    This statement is being filed to report the fact that as of the date hereof Eventide Asset Management, LLC has ceased to be the beneficial owner of more than five percent of the Issuer’s outstanding Common Stock.

    Item 6.Ownership of More Than Five Percent on Behalf of Another Person:

    Not Applicable

    Item 7.Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company:

    Not Applicable

    Item 8. Identification and Classification of Members of the Group:

    Not Applicable

    Item 9. Notice of Dissolution of Group:

    Not Applicable

    Item 10.Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    In accordance with Rule 13d-4 of the Securities Exchange Act of 1934, each of the persons filing this statement expressly disclaim the beneficial ownership of the securities covered by this statement and the filing of this report shall not be construed as an admission by such persons that they are the beneficial owners of such securities.

     
     

    SIGNATURES

     

    The undersigned certify, after reasonable inquiry and to the best knowledge and belief of the undersigned, that the information set forth in this Statement is true, complete and correct. The undersigned agree to the filing of this single Statement on Schedule 13G.

     

    Eventide Asset Management, LLC

    Date: February 10, 2023                                    By: /s/ Jennifer Reiche

    Name: Jennifer Reiche

    Title: Chief Compliance Officer

     

    Finny Kuruvilla, M.D., Ph. D.

    Date: February 10, 2023                                    By: /s/ Finny Kuruvilla, M.D., Ph. D.

    Name: Finny Kuruvilla, M.D., Ph. D.

    Robin C. John

    Date: February 10, 2023                                    By: /s/ Robin C. John

    Name: Robin C. John

     
     

     

    EXHIBIT 1

    WHEREAS, in accordance with Rule 13d-1(k)(1) under the Securities and Exchange Act of 1934 (the "Act"), only one joint Statement and any amendments thereto need to be filed whenever one or more persons are required to file such a Statement or any amendments thereto pursuant to Section 13(d) of the Act with respect to the same securities, provided that said persons agree in writing that such Statement or amendments thereto is filed on behalf of each of them;

    NOW, THEREFORE, the parties hereto agree as follows:

    Eventide Asset Management, LLC, Finny Kuruvilla, M.D., Ph. D. and Robin C. John do hereby agree, in accordance with Rule 13d-1(k)(1) under the Act, to file a Statement on Schedule 13G relating to their ownership of the Common Stock of the Issuer, and do hereby further agree that said Statement on Schedule 13G shall be filed on behalf of each of them.

    Eventide Asset Management, LLC

    Date: February 10, 2023                                    By: /s/ Jennifer Reiche

    Name: Jennifer Reiche

    Title: Chief Compliance Officer

     

    Finny Kuruvilla, M.D., Ph. D.

    Date: February 10, 2023                                    By: /s/ Finny Kuruvilla, M.D., Ph. D.

    Name: Finny Kuruvilla, M.D., Ph. D.

    Robin C. John

    Date: February 10, 2023                                    By: /s/ Robin C. John

    Name: Robin C. John

    Get the next $RXDX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RXDX

    DatePrice TargetRatingAnalyst
    5/10/2023$160.00 → $200.00Buy → Hold
    Jefferies
    7/20/2022$51.00Buy
    Goldman
    6/10/2022$53.00Overweight
    Piper Sandler
    3/10/2022$50.00 → $52.00Outperform
    Credit Suisse
    3/10/2022$42.00 → $53.00Overweight
    Wells Fargo
    3/10/2022$47.00 → $55.00Outperform
    SVB Leerink
    2/11/2022$62.00Buy
    BTIG
    12/13/2021$46.00Outperform
    RBC Capital Mkts
    More analyst ratings

    $RXDX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cellino Appoints Chris Gibson to Board of Directors

      Cellino Biotech, Inc., a biotechnology company advancing autonomous, closed biomanufacturing for personalized regenerative medicines, today announced the appointment of Chris Gibson to the company's Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241024933617/en/Chris Gibson, Ph.D., Co-Founder & CEO, Recursion. (Photo credit: Recursion) Chris Gibson, Ph.D., is the Co-Founder and CEO of Recursion (NASDAQ:RXDX), a clinical-stage techbio company at the forefront of AI-driven drug discovery. Dr. Gibson has led a number of key partnerships for Recursion with leading pharma and tech companies, including Roche/Genente

      10/24/24 8:00:00 AM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merck Completes Acquisition of Prometheus Biosciences, Inc.

      Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn's disease and other autoimmune conditions Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the completion of the Prometheus Biosciences, Inc. ("Prometheus") (NASDAQ:RXDX) acquisition. Prometheus is now a wholly-owned subsidiary of Merck and the common stock of Prometheus will no longer be listed or traded on the Nasdaq Global Market. "The Prometheus acquisition accelerates our growing presence in immunology, augments our diverse pipeline and increases our ability to deliver patient value. This transaction is anoth

      6/16/23 4:04:00 PM ET
      $MRK
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prometheus Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Progress

      SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (NASDAQ:RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutics for the treatment of immune-mediated diseases, today reported financial results for the quarter ended March 31, 2023. Prometheus to be Acquired by Merck On April 15, 2023, Merck and Prometheus Biosciences entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire Prometheus for $200.00 per share in cash for a total equity value of approximately $10.8 billion. The transaction is expected to close in the th

      5/9/23 4:00:00 PM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RXDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Mckenna Mark C.

      4 - Prometheus Biosciences, Inc. (0001718852) (Issuer)

      6/16/23 4:00:25 PM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Stenhouse Mark

      4 - Prometheus Biosciences, Inc. (0001718852) (Issuer)

      6/16/23 4:00:32 PM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Hendrix Martin

      4 - Prometheus Biosciences, Inc. (0001718852) (Issuer)

      6/16/23 4:00:40 PM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RXDX
    SEC Filings

    See more
    • SEC Form 15-12G filed by Prometheus Biosciences Inc.

      15-12G - Prometheus Biosciences, Inc. (0001718852) (Filer)

      6/27/23 3:06:42 PM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25-NSE filed by Prometheus Biosciences Inc.

      25-NSE - Prometheus Biosciences, Inc. (0001718852) (Subject)

      6/16/23 9:13:06 AM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Prometheus Biosciences Inc.

      S-8 POS - Prometheus Biosciences, Inc. (0001718852) (Filer)

      6/16/23 9:12:56 AM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RXDX
    Leadership Updates

    Live Leadership Updates

    See more
    • Cellino Appoints Chris Gibson to Board of Directors

      Cellino Biotech, Inc., a biotechnology company advancing autonomous, closed biomanufacturing for personalized regenerative medicines, today announced the appointment of Chris Gibson to the company's Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241024933617/en/Chris Gibson, Ph.D., Co-Founder & CEO, Recursion. (Photo credit: Recursion) Chris Gibson, Ph.D., is the Co-Founder and CEO of Recursion (NASDAQ:RXDX), a clinical-stage techbio company at the forefront of AI-driven drug discovery. Dr. Gibson has led a number of key partnerships for Recursion with leading pharma and tech companies, including Roche/Genente

      10/24/24 8:00:00 AM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prometheus Biosciences Reports Second Quarter 2021 Financial Results and Highlights Recent Corporate Progress

      - Initiated Phase 2 study of PRA023 and its companion diagnostic in Ulcerative Colitis (UC) and Phase 2a study of PRA023 and its companion diagnostic in Crohn's disease (CD) - - Phase 1a trial results of PRA023 in normal healthy volunteers expected in fourth quarter 2021 - - Strong cash position of $304 million as of June 30, 2021 - SAN DIEGO, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (NASDAQ:RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, starting first with inflammatory bo

      8/11/21 4:01:00 PM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Psychedelic Science Leader Eleusis Announces Four New Board Appointments, Further Strengthening Leadership

      Eleusis, a clinical-stage life science company dedicated to unlocking the full therapeutic potential of psychedelics, today announced the appointment of four highly experienced business leaders to its board of directors. The new directors' deep expertise building high-growth, high-impact life science companies complements Eleusis's world-class leadership team. The appointees include: David Socks, former CEO of Phathom Pharmaceuticals, joining as Chair of the board Robert Hershberg, M.D., Ph.D., former CBO and CSO of Celgene John Tucker, CEO of SC Pharmaceuticals Esther van den Boom, Managing Partner at van den Boom & Associates "We are delighted to welcome these four exceptional d

      7/12/21 8:00:00 AM ET
      $RXDX
      $PASG
      $PHAT
      $ARQT
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)

    $RXDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Prometheus Biosciences downgraded by Jefferies with a new price target

      Jefferies downgraded Prometheus Biosciences from Buy to Hold and set a new price target of $200.00 from $160.00 previously

      5/10/23 6:31:59 AM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Goldman initiated coverage on Prometheus Biosciences with a new price target

      Goldman initiated coverage of Prometheus Biosciences with a rating of Buy and set a new price target of $51.00

      7/20/22 7:36:43 AM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Prometheus Biosciences with a new price target

      Piper Sandler initiated coverage of Prometheus Biosciences with a rating of Overweight and set a new price target of $53.00

      6/10/22 7:19:39 AM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RXDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Prometheus Biosciences Inc. (Amendment)

      SC 13G/A - Prometheus Biosciences, Inc. (0001718852) (Subject)

      3/8/23 5:02:07 PM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Prometheus Biosciences Inc. (Amendment)

      SC 13G/A - Prometheus Biosciences, Inc. (0001718852) (Subject)

      2/14/23 4:27:18 PM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Prometheus Biosciences Inc. (Amendment)

      SC 13G/A - Prometheus Biosciences, Inc. (0001718852) (Subject)

      2/14/23 3:01:42 PM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $RXDX
    Financials

    Live finance-specific insights

    See more
    • Prometheus Biosciences Announces Positive Results for PRA023 in Both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a Studies Enabling Pathway to Both First-in-Class and Best-in-Class Anti-TL1A mAb

      – ARTEMIS-UC trial met primary endpoint with 26.5% of patients on PRA023 achieving clinical remission compared to 1.5% of patients on placebo at Week 12 (p<0.0001) – – ARTEMIS-UC Cohort 1 met all ranked secondary endpoints – – APOLLO-CD trial showed 26.0% endoscopic response and 49.1% clinical remission rates (p=0.002 and p<0.001, respectively, compared to prespecified historical placebo rates) – – PRA023 demonstrated favorable safety and tolerability results across both studies with no safety signal identified – – ARTEMIS-UC Cohort 1 interim analysis suggests a trend towards increased PRA023 response in CDx+ patients over all comers – – PRA023 showed a significant impact on multiple m

      12/7/22 7:00:00 AM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Prometheus Biosciences Reports Positive Topline Phase 1 Data on Lead Therapeutic Candidate PRA023; Expands Indications to Include Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)

      Phase 1 trial achieved primary objective of safety and tolerability and demonstrated favorable outcomes on other key endpoints, including target engagement and immunogenicity Discussion of Phase 1 results and rationale around SSc-ILD as new PRA023 indication to be presented in conference call scheduled today at 8:00 AM EST SAN DIEGO, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (NASDAQ:RXDX), a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases, today reported positive topline results fro

      12/7/21 7:00:00 AM ET
      $RXDX
      Biotechnology: Pharmaceutical Preparations
      Health Care